Cohance Lifesciences' Q1 FY 2026-27 Quarterly Results

Result Summary

• Cohance Lifesciences Ltd reported a 29.6% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a decline of 22.9%.
• Its expenses for the quarter were down by 17.8% QoQ and 3.1% YoY.
• The net profit decreased 643.8% QoQ and decreased 197.4% YoY.
• The earnings per share (EPS) of Cohance Lifesciences Ltd declined at 0.65 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Cohance Lifesciences Ltd is a company operating within the pharmaceutical and biotechnology industry. As a participant in this sector, it primarily focuses on developing and manufacturing healthcare products. The company is involved in producing a range of pharmaceutical products that cater to various therapeutic segments. Currently, specific recent developments or major product launches within the company are not available. As a company in the life sciences sector, it is likely that its activities are heavily influenced by research and development, regulatory approvals, and market demand for healthcare solutions.

Revenue

For the first quarter of fiscal year 2027 (Q1FY27), Cohance Lifesciences Ltd reported a total income of ₹434.51 crores. This represents a quarter-over-quarter (QoQ) decrease of 29.6% from the previous quarter (Q4FY26), where the total income was ₹617.28 crores. Additionally, there was a year-over-year (YoY) decline of 22.9% compared to Q1FY26, which recorded a total income of ₹563.48 crores. The downward trend in revenue over both the quarterly and yearly comparisons indicates changes in market conditions or sales performance during this period.

Profitability

In terms of profitability, Cohance Lifesciences Ltd experienced a notable decline during Q1FY27. The company reported a loss before tax of ₹42.87 crores, contrasting significantly with a profit before tax of ₹19.91 crores in Q4FY26 and ₹62.76 crores in Q1FY26. This reflects a QoQ decrease of 315.3% and a YoY decrease of 168.3%. The tax expense for Q1FY27 was ₹2.32 crores, which is substantially lower than the ₹11.60 crores in Q4FY26 and ₹16.36 crores in Q1FY26, decreasing by 80.0% QoQ and 85.8% YoY. Consequently, the profit after tax for Q1FY27 was a loss of ₹45.19 crores, a substantial shift from the profit of ₹8.31 crores in Q4FY26 and ₹46.40 crores in Q1FY26, representing a QoQ decrease of 643.8% and a YoY decrease of 197.4%.

Operating Metrics

The company's earnings per share (EPS) for Q1FY27 was reported at a negative ₹0.65, compared to a positive ₹0.50 in Q4FY26 and ₹1.27 in Q1FY26, indicating a QoQ decrease of 230.0% and a YoY decrease of 151.2%. This decline in EPS aligns with the observed decreases in profitability metrics. Total expenses for Q1FY27 were ₹477.38 crores, down 17.8% from ₹580.86 crores in Q4FY26 and slightly down by 3.1% from ₹492.62 crores in Q1FY26. The reduction in total expenses, while notable, was not sufficient to offset the declines in revenue, leading to a negative impact on the company's overall financial performance for the quarter.